FDA Approved: MAYZENT — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved a supplemental application for Mayzent (siponimod) submitted by Novartis Pharmaceuticals Corporation. The submission is for NDA 209884.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• MAYZENT (siponimod)

Snippet

SUPPL AP for MAYZENT (SIPONIMOD)